CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL by Wordsworth, P, van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Ballal, S, Kupper, H, Wong, R, Sieper, J

Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-... by van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Wordsworth, P, Ballal, S, Kupper, H, Wong, R, Sieper, J, Grp, A

Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas by Wordsworth, P, Dijkmans, B, van der Heijde, D, Davis, J, Schiff, M, Kivitz, A, Sieper, J, Mease, P, Kupper, H, Wong, R, Grp, A

Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. by van der Heijde, D, Kivitz, A, Schiff, M, Sieper, J, Dijkmans, B, Braun, J, Dougados, M, Wordsworth, P, Wong, R, Kupper, H, Davis, J